What is HC Wainwright’s Forecast for TLX FY2025 Earnings?

Telix Pharmaceuticals Limited (NASDAQ:TLX) – Research analysts at HC Wainwright dropped their FY2025 earnings per share estimates for shares of Telix Pharmaceuticals in a research report issued on Wednesday, January 21st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of $0.09 for the year, down from their prior estimate of $0.19. HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Telix Pharmaceuticals’ current full-year earnings is $0.24 per share. HC Wainwright also issued estimates for Telix Pharmaceuticals’ FY2026 earnings at $0.32 EPS.

TLX has been the topic of a number of other reports. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday. Finally, Wall Street Zen raised Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

Telix Pharmaceuticals Stock Down 0.1%

Telix Pharmaceuticals stock opened at $7.61 on Friday. The company has a fifty day simple moving average of $8.44 and a 200-day simple moving average of $10.36. Telix Pharmaceuticals has a 52-week low of $7.16 and a 52-week high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its holdings in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals in the 2nd quarter valued at about $213,000. Blair William & Co. IL acquired a new position in Telix Pharmaceuticals in the second quarter valued at about $217,000. JPMorgan Chase & Co. acquired a new position in Telix Pharmaceuticals in the third quarter valued at about $243,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Telix Pharmaceuticals during the second quarter worth about $297,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.